IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v42y2022i7p906-922.html

Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias

Author

Listed:
  • Howard Thom

    (Bristol Medical School, University of Bristol, UK (HT); Clifton Insight, Bristol, UK)

  • Joy Leahy

    (National Centre for Pharmacoeconomic, Dublin, Ireland)

  • Jeroen P. Jansen

    (School of Pharmacy, University of California, San Francisco, USA)

Abstract

Background Network meta-analysis (NMA) requires a connected network of randomized controlled trials (RCTs) and cannot include single-arm studies. Regulators or academics often have only aggregate data. Two aggregate data methods for analyzing disconnected networks are random effects on baseline and aggregate-level matching (ALM). ALM has been used only for single-arm studies, and both methods may bias effect estimates. Methods We modified random effects on baseline to separate RCTs connected to and disconnected from the reference and any single-arm studies, minimizing the introduction of bias. We term our modified method reference prediction . We similarly modified ALM and extended it to include RCTs disconnected from the reference. We tested these methods using constructed data and a simulation study. Results In simulations, bias for connected treatments for ALM ranged from −0.0158 to 0.051 and for reference prediction from −0.0107 to 0.083. These were low compared with the true mean effect of 0.5. Coverage ranged from 0.92 to 1.00. In disconnected treatments, bias of ALM ranged from −0.16 to 0.392 and of reference prediction from −0.102 to 0.40, whereas coverage of ALM ranged from 0.30 to 0.82 and of reference prediction from 0.64 to 0.94. Under fixed study effects for disconnected evidence, bias was similar, but coverage was 0.81 to 1.00 for reference prediction and 0.18 to 0.76 for ALM. Trends of similar bias but greater coverage for reference prediction with random study effects were repeated in constructed data. Conclusions Both methods with random study effects seem to minimize bias in treatment connected to the reference. They can estimate treatment effects for disconnected treatments but may be biased. Reference prediction has greater coverage and may be recommended overall. Highlights Two methods were modified for network meta-analysis on disconnected networks and for including single-arm observational or interventional studies in network meta-analysis using only aggregate data and for minimizing the bias of effect estimates for treatments only in trials connected to the reference. Reference prediction was developed as a modification of random effects on baseline that keeps analyses of trials connected to the reference separately from those disconnected from the reference and from single-arm studies. The method was further modified to account for correlation in trials with more than 2 arms and, under random study effects, to estimate variance in heterogeneity separately in connected and disconnected evidence. Aggregate-level matching was extended to include trials disconnected from the reference, rather than only single-arm studies. The method was further modified to separately estimate treatment effects and heterogeneity variance in the connected and disconnected evidence and to account for the correlation between arms in trials with more than 2 arms. Performance was assessed using a constructed data example and simulation study. The methods were found to have similar, and sometimes low, bias when estimating the relative effects for disconnected treatments, but reference prediction with random study effects had the greatest coverage. The use of reference prediction with random study effects for disconnected networks is recommended if no individual patient data or alternative real-world evidence is available.

Suggested Citation

  • Howard Thom & Joy Leahy & Jeroen P. Jansen, 2022. "Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias," Medical Decision Making, , vol. 42(7), pages 906-922, October.
  • Handle: RePEc:sae:medema:v:42:y:2022:i:7:p:906-922
    DOI: 10.1177/0272989X221097081
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X221097081
    Download Restriction: no

    File URL: https://libkey.io/10.1177/0272989X221097081?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Hugo Pedder & Sofia Dias & Meg Bennetts & Martin Boucher & Nicky J. Welton, 2021. "Joining the Dots: Linking Disconnected Networks of Evidence Using Dose-Response Model-Based Network Meta-Analysis," Medical Decision Making, , vol. 41(2), pages 194-208, February.
    2. David M. Phillippo & Anthony E. Ades & Sofia Dias & Stephen Palmer & Keith R. Abrams & Nicky J. Welton, 2018. "Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal," Medical Decision Making, , vol. 38(2), pages 200-211, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Manuel Gomes & Nick Latimer & Marta Soares & Sofia Dias & Gianluca Baio & Nick Freemantle & Dalia Dawoud & Allan Wailoo & Richard Grieve, 2022. "Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges," PharmacoEconomics, Springer, vol. 40(6), pages 577-586, June.
    2. B. Muresan & C. Mamolo & J. C. Cappelleri & M. J. Postma & B. Heeg, 2021. "Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 929-940, November.
    3. Dasom Lee & Shu Yang & Lin Dong & Xiaofei Wang & Donglin Zeng & Jianwen Cai, 2023. "Improving trial generalizability using observational studies," Biometrics, The International Biometric Society, vol. 79(2), pages 1213-1225, June.
    4. Ying Liu & Xiaoning He & Jia Liu & Jing Wu, 2025. "Is the Use of Unanchored Matching-Adjusted Indirect Comparison Always Superior to Naïve Indirect Comparison on Survival Outcomes? A Simulation Study," Applied Health Economics and Health Policy, Springer, vol. 23(4), pages 693-704, July.
    5. Pingyu Chen & Mengjie Luo & Yanqiu Chen & Yanlei Zhang & Chao Wang & Hongchao Li, 2024. "Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China," Health Economics Review, Springer, vol. 14(1), pages 1-10, December.
    6. Alex J. Turner & Cormac Sammon & Nick Latimer & Blythe Adamson & Brennan Beal & Vivek Subbiah & Keith R. Abrams & Joshua Ray, 2024. "Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments," PharmacoEconomics, Springer, vol. 42(2), pages 165-176, February.
    7. Jiyeon Kang & John Cairns, 2023. "“Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England," PharmacoEconomics - Open, Springer, vol. 7(1), pages 77-91, January.
    8. Sanjay Popat & Stephen V. Liu & Nicolas Scheuer & Grace G. Hsu & Alexandre Lockhart & Sreeram V. Ramagopalan & Frank Griesinger & Vivek Subbiah, 2022. "Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    9. Nan Qiao & Ralph Insinga & Thomas Burke & Gilberto Lopes, 2021. "Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective," PharmacoEconomics - Open, Springer, vol. 5(4), pages 765-778, December.
    10. Doug Coyle & Isabelle Durand-Zaleski & Jasmine Farrington & Louis Garrison & Johann-Matthias Graf von der Schulenburg & Wolfgang Greiner & Louise Longworth & Aurélie Meunier & Anne-Sophie Moutié & Ste, 2020. "HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1421-1437, December.

    More about this item

    Keywords

    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:42:y:2022:i:7:p:906-922. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.